Precigen (PGEN) Acquisitions (2013 - 2018)

Precigen (PGEN) posted quarterly Acquisitions of $920000.0 for Q4 2018, down 90.26% quarter-over-quarter from $9.4 million in Q4 2015.

Analysis

Precigen (PGEN) Acquisitions (2013 - 2018) Analysis & Trends

Precigen (PGEN) has reported Acquisitions for 4 consecutive years, with $920000.0 the latest figure, recorded in Q4 2018.

In Q4 2018, Acquisitions changed N/A year-over-year to $920000.0; the TTM figure through Dec 2018 stood at $920000.0 (changed N/A YoY), while the FY2018 annual figure was $920000.0, up 144.79% from the prior year.
Acquisitions retreated to $920000.0 in Q4 2018 per PGEN's latest filing, from $9.4 million in the prior quarter.
Across five years, Acquisitions topped out at $75.0 million in Q3 2015 and bottomed at $460000.0 in Q4 2014.
Historically, Acquisitions has averaged $24.1 million across 3 years, with a median of $9.7 million in 2015.
Annual changes were most pronounced in 2014 — Acquisitions surged 9300.0% — and 2015, when it climbed 20.54%.
Precigen's Acquisitions stood at $460000.0 in 2014, then jumped by 1953.91% to $9.4 million in 2015, then tumbled by 90.26% to $920000.0 in 2018.
Business Quant data shows PGEN's Acquisitions at $920000.0 in Q4 2018, $9.4 million in Q4 2015, and $75.0 million in Q3 2015.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	-
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Precigen	2.53 Bn	2.53 Bn	52.17 Mn	-

Historic Data

Download Data